Innovent Biologics, Inc. (HKG:1801)

Innovent Biologics Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 9, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	170,589	59,956	69,333	51,403	70,547	115,098
Market Cap Growth	116.33%	-13.53%	34.88%	-27.14%	-38.71%	243.36%
Enterprise Value	163,838	54,283	63,850	44,899	59,352	109,367
Last Close Price	99.60	36.60	42.75	33.50	48.25	82.05
PS Ratio	13.63	5.98	10.14	9.98	13.46	25.21
PB Ratio	10.79	4.30	5.02	4.24	5.56	11.04
P/TBV Ratio	11.94	4.40	5.04	4.25	5.57	11.04
P/FCF Ratio	-	175.32	-	-	-	-
P/OCF Ratio	-	43.78	425.78	-	-	-
EV/Sales Ratio	13.09	5.41	9.34	8.72	11.33	23.96
EV/EBITDA Ratio	106.12	2126.28	-	-	-	-
EV/FCF Ratio	-	158.73	-	-	-	-
Debt / Equity Ratio	0.23	0.22	0.29	0.30	0.24	0.14
Debt / EBITDA Ratio	2.29	50.93	-	-	-	-
Debt / FCF Ratio	-	8.81	-	-	-	-
Asset Turnover	0.52	0.45	0.33	0.27	0.30	0.40
Inventory Turnover	2.97	2.69	1.51	1.00	1.19	1.45
Quick Ratio	2.25	2.08	2.68	2.78	3.27	5.85
Current Ratio	2.61	2.35	3.00	3.29	3.79	6.37
Return on Equity (ROE)	8.43%	-0.74%	-8.84%	-20.70%	-28.56%	-14.75%
Return on Assets (ROA)	3.44%	-0.82%	-5.12%	-11.54%	-12.04%	-3.65%
Return on Capital (ROIC)	4.49%	-1.08%	-6.49%	-14.57%	-14.81%	-4.46%
Earnings Yield	0.73%	-0.17%	-1.63%	-4.79%	-4.75%	-1.03%
FCF Yield	-	0.57%	-1.54%	-6.19%	-5.38%	-0.82%
Buyback Yield / Dilution	-3.74%	-4.35%	-4.67%	-2.37%	-7.27%	-15.23%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.